Analysts Turn More Constructive on Johnson & Johnson (JNJ) Heading Into 2026

Johnson & Johnson (NYSE:JNJ) is among the most profitable US stocks to buy. On January 9, Lee Hambright at Bernstein raised the price target on Johnson & Johnson (NYSE:JNJ) to $208 from $193 and kept the ‘Market Perform’ rating unchanged, according to TheFly.

The firm noted that U.S. healthcare stocks have shown improved performance over the last few months, following a low point in September 2025. With clearer visibility into macroeconomic uncertainties that have challenged healthcare stocks throughout 2025, Bernstein has a more favorable outlook for 2026.

Three days earlier, on January 6, Stifel also raised the price target on Johnson & Johnson (NYSE:JNJ) to $205 from $190, keeping a ‘Hold’ rating on the stock. This upward revision in target follows the company’s completion of its approximately $3.05 billion acquisition of Halda Therapeutics on December 29, 2025.

Stifel highlighted that the Halda acquisition is projected to be dilutive to Johnson & Johnson’s (NYSE:JNJ) adjusted earnings per share by a total of $0.20, with $0.10 of the impact in each of 2025 and 2026.

Johnson & Johnson (NYSE:JNJ) is a global healthcare company focused on innovative medicines and medical technologies. Headquartered in New Jersey, the company serves a wide clientele, including retailers, wholesalers, healthcare professionals, and hospitals.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.